

# Irene Wessel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2387984/publications.pdf>

Version: 2024-02-01

71  
papers

1,291  
citations

393982

19  
h-index

395343

33  
g-index

72  
all docs

72  
docs citations

72  
times ranked

1624  
citing authors

#	ARTICLE	IF	CITATIONS
1	Swallowing Exercise During Head and Neck Cancer Treatment: Results of a Randomized Trial. <i>Dysphagia</i> , 2022, 37, 749-762.	1.0	21
2	Health-Related Quality of Life, Dysphagia, Voice Problems, Depression, and Anxiety After Total Laryngectomy. <i>Laryngoscope</i> , 2022, 132, 980-988.	1.1	13
3	Needs assessment in patients surgically treated for head and neck cancer—a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2022, 30, 4201-4218.	1.0	1
4	The impact of tobacco smoking on survival of patients with oral squamous cell carcinoma: a population-based retrospective study. <i>Acta Oncologica</i> , 2022, 61, 449-458.	0.8	6
5	Second primary cancer following primary oral squamous cell carcinoma: a population-based, retrospective study. <i>Acta Oncologica</i> , 2022, 61, 916-921.	0.8	4
6	The Voice-Related Quality of Life (V-RQOL) Instrument: Cross-Cultural Translation and Test of Validity and Reliability of the Danish Version. <i>Journal of Voice</i> , 2021, 35, 806.e7-806.e14.	0.6	7
7	The impact of comorbidities on survival in oral cancer patients: a population-based, case-control study. <i>Acta Oncologica</i> , 2021, 60, 173-179.	0.8	4
8	Long-term quality of life & functional outcomes after treatment of oropharyngeal cancer. <i>Cancer Medicine</i> , 2021, 10, 483-495.	1.3	16
9	European white paper: oropharyngeal dysphagia in head and neck cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 577-616.	0.8	66
10	Health-Related Quality of Life Following Total Laryngectomy: A Systematic Review. <i>Laryngoscope</i> , 2021, 131, 820-831.	1.1	18
11	Manuscript title: the maxillary swing approach – the first Scandinavian experience. <i>Acta Oto-Laryngologica</i> , 2021, 141, 519-530.	0.3	0
12	Sinonasal cancer in Denmark 2008–2015: a population-based phase-4 cohort study from DAHANCA. <i>Acta Oncologica</i> , 2021, 60, 333-342.	0.8	8
13	Danish translation of the Neck Dissection Impairment Index. <i>Acta Oto-Laryngologica</i> , 2021, 141, 646-648.	0.3	2
14	Lymphoma of the Uvula: Clinical, Morphological, Histopathological, and Genetic Characterization. A Nationwide Danish Study From 1980 to 2019. <i>Frontiers in Surgery</i> , 2021, 8, 675279.	0.6	2
15	Impact of delay in diagnosis and treatment-initiation on disease stage and survival in oral cavity cancer: a systematic review. <i>Acta Oncologica</i> , 2021, 60, 1083-1090.	0.8	14
16	Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma. <i>European Journal of Radiology</i> , 2021, 139, 109668.	1.2	4
17	The nurse-patient interaction during rehabilitation consultations in patients surgically treated for head and neck cancer—a qualitative study. <i>European Journal of Oncology Nursing</i> , 2021, 53, 101985.	0.9	2
18	Impact of time to treatment initiation for patients with oral cavity squamous cell carcinoma: a population-based, retrospective study. <i>Acta Oncologica</i> , 2021, 60, 491-496.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Submandibular ectopic thyroid tissue and concurrent thyroid hemiagenesis. <i>Acta Oto-Laryngologica Case Reports</i> , 2021, 6, 91-95.	0.1	1
20	Nutrition screening and assessment tools for patients with cancer and survivors of cancer: a systematic review protocol. <i>BMJ Open</i> , 2020, 10, e037844.	0.8	2
21	Impact of p16-overexpression on overall and progression-free survival outcomes in oral cavity squamous cell carcinomas: A semi-national, population-based study. <i>Oral Oncology</i> , 2020, 111, 105031.	0.8	6
22	Effects of a Multidisciplinary Residential Nutritional Rehabilitation Program in Head and Neck Cancer Survivors—Results from the NUTRI-HAB Randomized Controlled Trial. <i>Nutrients</i> , 2020, 12, 2117.	1.7	8
23	Lymphoma of the Sublingual Gland: Clinical, Morphological, Histopathological, and Genetic Characterization. <i>Frontiers in Surgery</i> , 2020, 7, 581105.	0.6	5
24	Quality of Life and Functional Outcomes after Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 1216.	0.4	0
25	Association between multimodal functional imaging and intratumor heterogeneity of immunohistochemistry in head and neck squamous cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 1169-1170.	0.4	0
26	Microvascular reconstruction in head and neck cancer - basis for the development of an enhanced recovery protocol. <i>JPRAS Open</i> , 2020, 26, 91-100.	0.4	7
27	Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?. <i>British Journal of Cancer</i> , 2020, 123, 46-53.	2.9	13
28	Rationale and design of a randomised controlled trial investigating the effect of multidisciplinary nutritional rehabilitation for patients treated for head and neck cancer (the NUTRI-HAB trial). <i>Nutrition Journal</i> , 2020, 19, 21.	1.5	3
29	Electrochemotherapy in the head and neck area: an addition to the treatment armamentarium. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2020, 28, 112-117.	0.8	9
30	Impact of p16-overexpression on overall and progression free survival outcomes in oral cavity squamous cell carcinomas: A semi-national, population based study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 1149-1150.	0.4	1
31	Patients' and health professionals' experience of the Danish fast track treatment pathway for head and neck cancer patients receiving oral rehabilitation. <i>Acta Odontologica Scandinavica</i> , 2020, 78, 362-369.	0.9	2
32	The Impact of Comorbidity on Survival in Patients With Head and Neck Squamous Cell Carcinoma: A Nationwide Case-Control Study Spanning 35 Years. <i>Frontiers in Oncology</i> , 2020, 10, 617184.	1.3	10
33	The DAHANCA 32 study: Electrochemotherapy for recurrent mucosal head and neck cancer. <i>Head and Neck</i> , 2019, 41, 329-339.	0.9	16
34	PD-030 Does multiparametric imaging with FDG-PET/MRI capture intratumor heterogeneity in histopathology?. <i>Radiotherapy and Oncology</i> , 2019, 132, 17-18.	0.3	0
35	PO-106 Intratumor heterogeneity of PD-L1 expression in Head and Neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 132, 53-54.	0.3	0
36	PET/CT prior to salvage surgery in recurrent head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 2895-2902.	0.8	5

#	ARTICLE	IF	CITATIONS
37	&lt;p&gt;The Copenhagen Oral Cavity Squamous Cell Carcinoma database: protocol and report on establishing a comprehensive oral cavity cancer database&lt;/p&gt;. <i>Clinical Epidemiology</i> , 2019, Volume 11, 733-741.	1.5	13
38	To eat is to practiceâ€”managing eating problems after head and neck cancer. <i>Journal of Cancer Survivorship</i> , 2019, 13, 792-803.	1.5	22
39	Calcium electroporation for recurrent head and neck cancer: A clinical phase I study. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 49-56.	0.6	39
40	Oral healthâ€related quality of life, oral aesthetics and oral function in head and neck cancer patients after oral rehabilitation. <i>Journal of Oral Rehabilitation</i> , 2019, 46, 738-746.	1.3	10
41	Salivary gland carcinomas with unusual presentations. <i>Acta OncolÃ³gica</i> , 2019, 58, 382-384.	0.8	0
42	An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome. <i>Apmsis</i> , 2019, 127, 240-264.	0.9	26
43	Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 1003-1006.	2.9	109
44	Adherence to preventive swallowing exercises for head and neck cancer patients undergoing (chemo)radiotherapy treatment. <i>Acta OncolÃ³gica</i> , 2019, 58, 658-664.	0.8	15
45	The HTN3-MSANTD3 Fusion Gene Defines a Subset of Acinic Cell Carcinoma of the Salivary Gland. <i>American Journal of Surgical Pathology</i> , 2019, 43, 489-496.	2.1	52
46	Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles. <i>Modern Pathology</i> , 2018, 31, 1211-1225.	2.9	33
47	The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA. <i>Cancer Cytopathology</i> , 2018, 126, 275-281.	1.4	26
48	Otitis media with effusion after radiotherapy of the head and neck: a systematic review. <i>Acta OncolÃ³gica</i> , 2018, 57, 1011-1016.	0.8	17
49	MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 329-340.	1.4	26
50	Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland. <i>Oncotarget</i> , 2018, 9, 19675-19687.	0.8	15
51	Swallowing therapy and progressive resistance training in head and neck cancer patients undergoing radiotherapy treatment: randomized control trial protocol and preliminary data. <i>Acta OncolÃ³gica</i> , 2017, 56, 354-359.	0.8	14
52	Cross-Cultural Translation, Adaptation and Reliability of the Danish M. D. Anderson Dysphagia Inventory (MDADI) in Patients with Head and Neck Cancer. <i>Dysphagia</i> , 2017, 32, 472-479.	1.0	9
53	Increasing incidence and survival in oral cancer: a nationwide Danish study from 1980 to 2014. <i>Acta OncolÃ³gica</i> , 2017, 56, 1204-1209.	0.8	31
54	Head and neck cancer management in the Nordic countries: an effort to harmonize treatment. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 2363-2365.	0.8	6

#	ARTICLE	IF	CITATIONS
55	PO-095: Electrochemotherapy for mucosal head and neck tumours: results from a phase II clinical trial.. Radiotherapy and Oncology, 2017, 122, 45-46.	0.3	0
56	European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers. European Journal of Cancer, 2017, 87, 172-181.	1.3	72
57	Intraoperative Sentinel Lymph Node Evaluation: Implications of Cytokeratin 19 Expression for the Adoption of OSNA in Oral Squamous Cell Carcinoma. Annals of Surgical Oncology, 2016, 23, 4042-4048.	0.7	9
58	European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. European Journal of Cancer, 2016, 63, 41-52.	1.3	137
59	Electrochemotherapy of mucosal head and neck tumors: a systematic review. Acta Oncologica, 2016, 55, 1266-1272.	0.8	13
60	Incidence and Risk Factors of Refeeding Syndrome in Head and Neck Cancer Patients—An Observational Study. Nutrition and Cancer, 2016, 68, 1320-1329.	0.9	16
61	Tumors of the sublingual gland: a national clinicopathologic study of 29 cases. European Archives of Oto-Rhino-Laryngology, 2016, 273, 3847-3856.	0.8	29
62	Activation of the interleukin-6/Janus kinase/STAT3 pathway in pleomorphic adenoma of the parotid gland. Apms, 2015, 123, 706-715.	0.9	21
63	Dysphagia training after head and neck cancer fails to follow legislation and national recommendations. Danish Medical Journal, 2015, 62, .	0.5	2
64	Stability of the Topoisomerase II Closed Clamp Conformation May Influence DNA-stimulated ATP Hydrolysis. Journal of Biological Chemistry, 2005, 280, 11920-11929.	1.6	21
65	Maleimide Is a Potent Inhibitor of Topoisomerase II in Vitro and in Vivo: A New Mode of Catalytic Inhibition. Molecular Pharmacology, 2002, 61, 1235-1243.	1.0	46
66	Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II $\alpha$ . FEBS Letters, 2002, 520, 161-166.	1.3	22
67	N-terminal and core-domain random mutations in human topoisomerase II $\alpha$ conferring bisdioxopiperazine resistance. FEBS Letters, 2000, 480, 201-207.	1.3	18
68	Four out of six human NYH small cell lung cancer cell lines resistant to ICRF-187 have either R162Q or Y165S functional mutations in the Walker ATP binding site of topoisomerase II $\alpha$ . Lung Cancer, 2000, 29, 11.	0.9	1
69	Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer Research, 1999, 59, 3442-50.	0.4	38
70	Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Research, 1998, 58, 1460-8.	0.4	46
71	Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase II $\alpha$ in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Research, 1997, 57, 4451-4.	0.4	54